Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram

Détails

ID Serval
serval:BIB_9A46169C70F8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram
Périodique
European Neuropsychopharmacology
Auteur(s)
Baumann P., Zullino D.F., Eap C.B.
ISSN
0924-977X
Statut éditorial
Publié
Date de publication
2002
Peer-reviewed
Oui
Volume
12
Numéro
5
Pages
433-444
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
Stereochemistry is now influencing most areas of pharmacotherapy, with a growing awareness in the field of psychiatry and, more specifically, depression. This is due to the fact that the enantiomers of many chiral drugs may have distinct pharmacological, pharmacokinetic and/or pharmacogenetic profiles. Consequently, in some instances there may be an advantage in using a single enantiomer over the racemic form-thus providing a basis for the development of new therapeutic agents, as well as the potential to improve current treatments. This review highlights some of the potential advantages and disadvantages that using single enantiomers might offer. The principles are exemplified through reference to the stereoselective properties of several established chiral psychotropic drugs, including thioridazine, methadone, trimipramine, mianserin, mirtazapine, fluoxetine and citalopram. Emphasis is given to the treatment of depression and how the potential of one pure enantiomer-escitalopram, the S-enantiomer of the selective serotonin reuptake inhibitor citalopram-appears to be fulfilling its preclinical promise in the clinic.
Mots-clé
Animals, Antidepressive Agents, Second-Generation, Citalopram, Depression, Fluoxetine, Humans, Mental Disorders, Mianserin, Molecular Structure, Psychotropic Drugs, Serotonin Uptake Inhibitors, Stereoisomerism, Thioridazine, Trimipramine
Pubmed
Web of science
Création de la notice
10/03/2008 11:53
Dernière modification de la notice
20/08/2019 16:01
Données d'usage